Nevertheless, immune blockade of CD73 aiming to alter macrophage polarization in combination with inhibition of CTLA-4 and PD-1 to enhance T cell infiltration will favorably change the results of checkpoint therapy and most likely provide successful outcomes for GBM patients. This evidence concerns the gene NT5E and glioblastoma.